251 related articles for article (PubMed ID: 16055114)
1. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
[TBL] [Abstract][Full Text] [Related]
2. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
3. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
4. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
[TBL] [Abstract][Full Text] [Related]
5. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
Inan S; Cowan A
Pharmacol Biochem Behav; 2006 Sep; 85(1):39-43. PubMed ID: 16919318
[TBL] [Abstract][Full Text] [Related]
6. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
Inan S; Dun NJ; Cowan A
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576988
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
8. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.
Akiyama T; Carstens MI; Piecha D; Steppan S; Carstens E
Acta Derm Venereol; 2015 Feb; 95(2):147-50. PubMed ID: 24890341
[TBL] [Abstract][Full Text] [Related]
9. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
[TBL] [Abstract][Full Text] [Related]
10. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice.
Kamei J; Nagase H
Eur J Pharmacol; 2001 Apr; 418(1-2):141-5. PubMed ID: 11334876
[TBL] [Abstract][Full Text] [Related]
11. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
12. Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice.
Inan S; Dun NJ; Cowan A
Peptides; 2011 Feb; 32(2):286-92. PubMed ID: 21126550
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice.
Takano N; Arai I; Hashimoto Y; Kurachi M
Eur J Pharmacol; 2004 Jul; 495(2-3):159-65. PubMed ID: 15249165
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system.
Tarrasón G; Carcasona C; Eichhorn P; Pérez B; Gavaldà A; Godessart N
Exp Dermatol; 2017 Nov; 26(11):1105-1111. PubMed ID: 28605064
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
16. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
17. Targeting Itch with Ligands Selective for κ Opioid Receptors.
Cowan A; Kehner GB; Inan S
Handb Exp Pharmacol; 2015; 226():291-314. PubMed ID: 25861786
[TBL] [Abstract][Full Text] [Related]
18. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
19. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of scratching behavior in ADJM mice (atopic dermatitis from Japanese mice).
Nakasone T; Sato T; Matsushima Y; Inoue T; Kamei C
Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):202-6. PubMed ID: 25578901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
